dwinnex.com

The share price of Melinta Therapeutics, Inc. [NASDAQ: MLNT] inclined by $5.96, presently trading at $5.77. The company’s shares saw 256.17% gains compared to the lowest price in the period of the last 52 weeks, set at $1.62 recorded on 26/06/2019. The last few days have been tough to the share price as MLNT fall by -9.75% during the last week, even though the stock is still down by -23.88% compared to -0.63 of all time high it touched on 06/20/19. However, the stock had a strong performance during the past 3 months, roughly gaining 125.76%, while additionally dropping -83.21% during the last 12 months. Melinta Therapeutics, Inc. is said to have a 12-month price target set at $48.75. That means that the stock has a strong potential to acquire 42.98% increase from the current trading price.

Melinta Therapeutics, Inc. [NASDAQ:MLNT]: Analyst Rating and Earnings

Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Melinta Therapeutics, Inc. [MLNT], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of December. On average, stock market experts give MLNT an Hold rating. Its stock price has been found in the range of 1.62 to 35.00. This is compared to its latest closing price of $5.96.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Melinta Therapeutics, Inc. [MLNT] is sitting at 2.71. This is compared to 1 month ago, when its average rating was 2.50.

For the quarter ending in Mar-19 Melinta Therapeutics, Inc. [MLNT] generated $0.01 billion in sales. That’s 6.18% lower than the average estimate of $0.02 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Tue 6 Aug (In 41 Days).

Fundamental Analysis of Melinta Therapeutics, Inc. [MLNT]

Now let’s turn to look at profitability: with a current Operating Margin for Melinta Therapeutics, Inc. [MLNT] sitting at -133.91 and its Gross Margin at +57.42.

This company’s Return on Total Capital is -62.62, and its Return on Invested Capital has reached -51.80%. Its Return on Equity is -119.81, and its Return on Assets is -52.24. These metrics suggest that this Melinta Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Melinta Therapeutics, Inc. [MLNT] has generated a Total Debt to Total Equity ratio of 58.13. Similarly, its Total Debt to Total Capital is 36.76, while its Total Debt to Total Assets stands at 25.02. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 58.13, and its Long-Term Debt to Total Capital is 36.76. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -0.78. The Enterprise Value to Sales for this firm is now 0.92, and its Total Debt to Enterprise Value stands at 1.70. Melinta Therapeutics, Inc. [MLNT] has a Price to Book Ratio of 0.23.

Shifting the focus to workforce efficiency, Melinta Therapeutics, Inc. [MLNT] earns $332,517 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.42 and its Total Asset Turnover is 0.32. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.81 and its Current Ratio is 1.12. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.

Melinta Therapeutics, Inc. [MLNT] has 12.37M shares outstanding, amounting to a total market cap of $73.73M. Its stock price has been found in the range of 1.62 to 35.00. At its current price, it has moved down by -83.51% from its 52-week high, and it has moved up 256.17% from its 52-week low.

This stock’s Relative Strength Index (RSI) is at 66.69. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Melinta Therapeutics, Inc. [MLNT] a Reliable Buy?

Melinta Therapeutics, Inc. [MLNT] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.